Results 201 to 210 of about 293,672 (350)

Novel Vascularized Human Liver Organoids for Modeling Alcohol‐Induced Liver Injury and Developing Hepatoprotective Therapy

open access: yesAdvanced Science, EarlyView.
This study successfully engineered vascularized liver organoids (3HLOs) by co‐culturing human reprogrammed hepatocyte‐like cells (hrHLs) with human umbilical vein endothelial cells (HUVECs) and human umbilical mesenchymal stem cells (HUMSCs). Upon implantation, the 3HLOs established functional vascular anastomosis with the host circulation and ...
Kangdi Yang   +13 more
wiley   +1 more source

KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression

open access: yesAdvanced Science, EarlyView.
Cholangiocarcinoma (CCA) driven by oncogenic KRAS depends on its continuous activation for tumor maintenance. Using a conditional KRAS model, the authors show that turning off KRAS triggers rapid tumor regression accompanied by immune cell infiltration and cytokine release. The findings uncover a KRAS–senescence–immune signaling axis and highlight KRAS
Youwei Qiao   +9 more
wiley   +1 more source

Detection and Proinflammatory Effects of BTEX within the Human Atherosclerotic Plaque. [PDF]

open access: yesEnviron Sci Technol
Marfella R   +30 more
europepmc   +1 more source

Elemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis

open access: yesAdvanced Science, EarlyView.
Elemene increases SPP expression by competitively binding with miR‐130a‐5p to suppress SPP mRNA degradation. This led to more antigen/MHC‐I complexes being expressed on the cell surface, which consequently facilitated the recognition and killing of HCC cells by CTLs and enhancing the antitumor immune efficacy of anti‐PD‐1.
Menglan Wang   +18 more
wiley   +1 more source

Guest-Induced PhaseSwitching in a Square LatticeCoordination Network to Enable Selective Adsorption of p‑Xylene

open access: green
Shi-Qiang Wang (205491)   +9 more
openalex   +1 more source

Home - About - Disclaimer - Privacy